Targeting Interleukin-6 Signaling in Clinic

Immunity

Volumn 50, Issue 4, 2019, Pages 1007-1023

  Kang, Sujin ^a   Tanaka, Toshio ^b   Narazaki, Masashi ^a,c   Kishimoto, Tadamitsu ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

acute; cancer; chronic; gp130; IL 6; IL 6 receptor; inflammation

Indexed keywords

CYTOKINE RECEPTOR ANTAGONIST; INTERLEUKIN 6; INTERLEUKIN 6 INHIBITOR; INTERLEUKIN 6 RECEPTOR; UNCLASSIFIED DRUG; GLYCOPROTEIN GP 130; IL6 PROTEIN, HUMAN; INTERLEUKIN-6, MOUSE; JANUS KINASE; MONOCLONAL ANTIBODY; RIBONUCLEASE; SOCS1 PROTEIN, HUMAN; SOCS3 PROTEIN, HUMAN; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; ZC3H12A PROTEIN, MOUSE;

CLINICAL DECISION MAKING; DRUG SAFETY; HUMAN; IMMUNOBIOLOGY; INTERFERON PRODUCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; CLINICAL TRIAL (TOPIC); DRUG EFFECT; IMMUNOLOGY; INFLAMMATION; KNOCKOUT MOUSE; MAPK SIGNALING; MOLECULARLY TARGETED THERAPY; MOUSE; PHYSIOLOGY; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; CYTOKINE RECEPTOR GP130; HUMANS; INFLAMMATION; INTERLEUKIN-6; JANUS KINASES; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; RECEPTORS, INTERLEUKIN-6; RIBONUCLEASES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING 1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3 PROTEIN;

EID: 85064006062     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2019.03.026     Document Type: Review

References (149)

1. Akira, S., Kishimoto, T., IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol. Rev. 127 (1992), 25–50.
2. Anderson, P., Post-transcriptional control of cytokine production. Nat. Immunol. 9 (2008), 353–359.
3. Anderson, P., Post-transcriptional regulons coordinate the initiation and resolution of inflammation. Nat. Rev. Immunol. 10 (2010), 24–35.
4. Araki, M., Matsuoka, T., Miyamoto, K., Kusunoki, S., Okamoto, T., Murata, M., Miyake, S., Aranami, T., Yamamura, T., Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 82 (2014), 1302–1306.
5. Babon, J.J., Kershaw, N.J., Murphy, J.M., Varghese, L.N., Laktyushin, A., Young, S.N., Lucet, I.S., Norton, R.S., Nicola, N.A., Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity 36 (2012), 239–250.
6. Basu, R., Brar, J.S., Chengappa, K.N., John, V., Parepally, H., Gershon, S., Schlicht, P., Kupfer, D.J., The prevalence of the metabolic syndrome in patients with schizoaffective disorder–bipolar subtype. Bipolar Disord. 6 (2004), 314–318.
7. Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T.B., Oukka, M., Weiner, H.L., Kuchroo, V.K., Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441 (2006), 235–238.
8. Bijlsma, J.W.J., Welsing, P.M.J., Woodworth, T.G., Middelink, L.M., Pethö-Schramm, A., Bernasconi, C., Borm, M.E.A., Wortel, C.H., Ter Borg, E.J., Jahangier, Z.N., et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 388 (2016), 343–355.
9. Brandt, S.J., Bodine, D.M., Dunbar, C.E., Nienhuis, A.W., Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J. Clin. Invest. 86 (1990), 592–599.
10. Brudno, J.N., Kochenderfer, J.N., Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127 (2016), 3321–3330.
11. Burmester, G.R., Rubbert-Roth, A., Cantagrel, A., Hall, S., Leszczynski, P., Feldman, D., Rangaraj, M.J., Roane, G., Ludivico, C., Lu, P., et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann. Rheum. Dis. 73 (2014), 69–74.
12. Burmester, G.R., Rigby, W.F., van Vollenhoven, R.F., Kay, J., Rubbert-Roth, A., Kelman, A., Dimonaco, S., Mitchell, N., Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann. Rheum. Dis. 75 (2016), 1081–1091.
13. Burmester, G.R., Lin, Y., Patel, R., van Adelsberg, J., Mangan, E.K., Graham, N.M., van Hoogstraten, H., Bauer, D., Ignacio Vargas, J., Lee, E.B., Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann. Rheum. Dis. 76 (2017), 840–847.
14. Burmester, G.R., Kremer, J.M., Van den Bosch, F., Kivitz, A., Bessette, L., Li, Y., Zhou, Y., Othman, A.A., Pangan, A.L., Camp, H.S., Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 391 (2018), 2503–2512.
15. Bykerk, V.P., Ostör, A.J., Alvaro-Gracia, J., Pavelka, K., Ivorra, J.A., Graninger, W., Bensen, W., Nurmohamed, M.T., Krause, A., Bernasconi, C., et al. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Ann. Rheum. Dis. 71 (2012), 1950–1954.
16. Changelian, P.S., Flanagan, M.E., Ball, D.J., Kent, C.R., Magnuson, K.S., Martin, W.H., Rizzuti, B.J., Sawyer, P.S., Perry, B.D., Brissette, W.H., et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302 (2003), 875–878.
17. Chase, K.A., Rosen, C., Gin, H., Bjorkquist, O., Feiner, B., Marvin, R., Conrin, S., Sharma, R.P., Metabolic and inflammatory genes in schizophrenia. Psychiatry Res. 225 (2015), 208–211.
18. Chen, F., Chen, D., Zhang, Y., Jin, L., Zhang, H., Wan, M., Pan, T., Wang, X., Su, Y., Xu, Y., Ye, J., Interleukin-6 deficiency attenuates angiotensin II-induced cardiac pathogenesis with increased myocyte hypertrophy. Biochem. Biophys. Res. Commun. 494 (2017), 534–541.
19. Chourbaji, S., Urani, A., Inta, I., Sanchis-Segura, C., Brandwein, C., Zink, M., Schwaninger, M., Gass, P., IL-6 knockout mice exhibit resistance to stress-induced development of depression-like behaviors. Neurobiol. Dis. 23 (2006), 587–594.
20. Choy, E.H., Isenberg, D.A., Garrood, T., Farrow, S., Ioannou, Y., Bird, H., Cheung, N., Williams, B., Hazleman, B., Price, R., et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 46 (2002), 3143–3150.
21. Choy, E.H., Kavanaugh, A.F., Jones, S.A., The problem of choice: current biologic agents and future prospects in RA. Nat. Rev. Rheumatol. 9 (2013), 154–163.
22. Ciofani, M., Madar, A., Galan, C., Sellars, M., Mace, K., Pauli, F., Agarwal, A., Huang, W., Parkhurst, C.N., Muratet, M., et al. A validated regulatory network for Th17 cell specification. Cell 151 (2012), 289–303.
23. Coort, S.L., Hasselbaink, D.M., Koonen, D.P., Willems, J., Coumans, W.A., Chabowski, A., van der Vusse, G.J., Bonen, A., Glatz, J.F., Luiken, J.J., Enhanced sarcolemmal FAT/CD36 content and triacylglycerol storage in cardiac myocytes from obese zucker rats. Diabetes 53 (2004), 1655–1663.
24. Cressman, D.E., Greenbaum, L.E., DeAngelis, R.A., Ciliberto, G., Furth, E.E., Poli, V., Taub, R., Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274 (1996), 1379–1383.
25. De Benedetti, F., Rucci, N., Del Fattore, A., Peruzzi, B., Paro, R., Longo, M., Vivarelli, M., Muratori, F., Berni, S., Ballanti, P., et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum. 54 (2006), 3551–3563.
26. De Benedetti, F., Brunner, H.I., Ruperto, N., Kenwright, A., Wright, S., Calvo, I., Cuttica, R., Ravelli, A., Schneider, R., Woo, P., et al. PRINTO, PRCSG. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367 (2012), 2385–2395.
27. Denton, C.P., Wells, A.U., Coghlan, J.G., Major lung complications of systemic sclerosis. Nat. Rev. Rheumatol. 14 (2018), 511–527.
28. Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K., Lanctôt, K.L., A meta-analysis of cytokines in major depression. Biol. Psychiatry 67 (2010), 446–457.
29. Ellingsgaard, H., Hauselmann, I., Schuler, B., Habib, A.M., Baggio, L.L., Meier, D.T., Eppler, E., Bouzakri, K., Wueest, S., Muller, Y.D., et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat. Med. 17 (2011), 1481–1489.
30. Emery, P., Keystone, E., Tony, H.P., Cantagrel, A., van Vollenhoven, R., Sanchez, A., Alecock, E., Lee, J., Kremer, J., IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67 (2008), 1516–1523.
31. Emery, P., Rondon, J., Parrino, J., Lin, Y., Pena-Rossi, C., van Hoogstraten, H., Graham, N.M.H., Liu, N., Paccaly, A., Wu, R., Spindler, A., Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. Rheumatology. 2018, Oxford.
32. Fitzgerald, J.C., Weiss, S.L., Maude, S.L., Barrett, D.M., Lacey, S.F., Melenhorst, J.J., Shaw, P., Berg, R.A., June, C.H., Porter, D.L., et al. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Crit. Care Med. 45 (2017), e124–e131.
33. Fizazi, K., De Bono, J.S., Flechon, A., Heidenreich, A., Voog, E., Davis, N.B., Qi, M., Bandekar, R., Vermeulen, J.T., Cornfeld, M., Hudes, G.R., Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur. J. Cancer 48 (2012), 85–93.
34. Fleischmann, R., van Adelsberg, J., Lin, Y., Castelar-Pinheiro, G.D., Brzezicki, J., Hrycaj, P., Graham, N.M., van Hoogstraten, H., Bauer, D., Burmester, G.R., Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol. 69 (2017), 277–290.
35. Gabay, C., Emery, P., van Vollenhoven, R., Dikranian, A., Alten, R., Pavelka, K., Klearman, M., Musselman, D., Agarwal, S., Green, J., Kavanaugh, A., ADACTA Study Investigators. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381 (2013), 1541–1550.
36. Gabay, C., McInnes, I.B., Kavanaugh, A., Tuckwell, K., Klearman, M., Pulley, J., Sattar, N., Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 75 (2016), 1806–1812.
37. Garbers, C., Heink, S., Korn, T., Rose-John, S., Interleukin-6: designing specific therapeutics for a complex cytokine. Nat. Rev. Drug Discov. 17 (2018), 395–412.
38. Genovese, M.C., Fleischmann, R., Furst, D., Janssen, N., Carter, J., Dasgupta, B., Bryson, J., Duncan, B., Zhu, W., Pitzalis, C., et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann. Rheum. Dis. 73 (2014), 1607–1615.
39. Genovese, M.C., Fleischmann, R., Kivitz, A.J., Rell-Bakalarska, M., Martincova, R., Fiore, S., Rohane, P., van Hoogstraten, H., Garg, A., Fan, C., et al. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. Arthritis Rheumatol. 67 (2015), 1424–1437.
40. Genovese, M.C., Fleischmann, R., Combe, B., Hall, S., Rubbert-Roth, A., Zhang, Y., Zhou, Y., Mohamed, M.F., Meerwein, S., Pangan, A.L., Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 391 (2018), 2513–2524.
41. 4 induced liver damage. Biochim. Biophys. Acta 1802 (2010), 1054–1061.
42. Gritsko, T., Williams, A., Turkson, J., Kaneko, S., Bowman, T., Huang, M., Nam, S., Eweis, I., Diaz, N., Sullivan, D., et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res. 12 (2006), 11–19.
43. Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, D.T., Chew, A., Hauck, B., Wright, J.F., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368 (2013), 1509–1518.
44. Harker, J.A., Lewis, G.M., Mack, L., Zuniga, E.I., Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection. Science 334 (2011), 825–829.
45. H 17 cells. Nat. Immunol. 18 (2017), 74–85.
46. Heinrich, P.C., Behrmann, I., Haan, S., Hermanns, H.M., Müller-Newen, G., Schaper, F., Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374 (2003), 1–20.
47. Hibi, M., Murakami, M., Saito, M., Hirano, T., Taga, T., Kishimoto, T., Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63 (1990), 1149–1157.
48. Higa, M., Oka, M., Fujihara, Y., Masuda, K., Yoneda, Y., Kishimoto, T., Regulation of inflammatory responses by dynamic subcellular localization of RNA-binding protein Arid5a. Proc. Natl. Acad. Sci. USA 115 (2018), E1214–E1220.
49. Hunter, C.A., Jones, S.A., IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 16 (2015), 448–457.
50. Jones, G., Sebba, A., Gu, J., Lowenstein, M.B., Calvo, A., Gomez-Reino, J.J., Siri, D.A., Tomsic, M., Alecock, E., Woodworth, T., Genovese, M.C., Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann. Rheum. Dis. 69 (2010), 88–96.
51. Kaneko, Y., Atsumi, T., Tanaka, Y., Inoo, M., Kobayashi-Haraoka, H., Amano, K., Miyata, M., Murakawa, Y., Yasuoka, H., Hirata, S., et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Ann. Rheum. Dis. 75 (2016), 1917–1923.
52. Karnowski, A., Chevrier, S., Belz, G.T., Mount, A., Emslie, D., D'Costa, K., Tarlinton, D.M., Kallies, A., Corcoran, L.M., B and T cells collaborate in antiviral responses via IL-6, IL-21, and transcriptional activator and coactivator, Oct2 and OBF-1. J. Exp. Med. 209 (2012), 2049–2064.
53. Khanna, D., Denton, C.P., Jahreis, A., van Laar, J.M., Frech, T.M., Anderson, M.E., Baron, M., Chung, L., Fierlbeck, G., Lakshminarayanan, S., et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 387 (2016), 2630–2640.
54. Kishimoto, T., Akira, S., Taga, T., Interleukin-6 and its receptor: a paradigm for cytokines. Science 258 (1992), 593–597.
55. Kivitz, A., Olech, E., Borofsky, M., Zazueta, B.M., Navarro-Sarabia, F., Radominski, S.C., Merrill, J.T., Rowell, L., Nasmyth-Miller, C., Bao, M., et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res. (Hoboken) 66 (2014), 1653–1661.
56. Klemettilä, J.P., Kampman, O., Seppälä, N., Viikki, M., Hämäläinen, M., Moilanen, E., Leinonen, E., Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine. Psychiatry Res. 218 (2014), 277–283.
57. Koike, T., Harigai, M., Inokuma, S., Ishiguro, N., Ryu, J., Takeuchi, T., Takei, S., Tanaka, Y., Sano, Y., Yaguramaki, H., Yamanaka, H., Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J. Rheumatol. 41 (2014), 15–23.
58. Kovacs, E., Investigation of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) in sera of cancer patients. Biomed. Pharmacother. 55 (2001), 391–396.
59. Kraakman, M.J., Kammoun, H.L., Allen, T.L., Deswaerte, V., Henstridge, D.C., Estevez, E., Matthews, V.B., Neill, B., White, D.A., Murphy, A.J., et al. Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. Cell Metab. 21 (2015), 403–416.
60. Kuhn, K.A., Manieri, N.A., Liu, T.C., Stappenbeck, T.S., IL-6 stimulates intestinal epithelial proliferation and repair after injury. PLoS ONE, 9, 2014, e114195.
61. Lamertz, L., Rummel, F., Polz, R., Baran, P., Hansen, S., Waetzig, G.H., Moll, J.M., Floss, D.M., Scheller, J., Soluble gp130 prevents interleukin-6 and interleukin-11 cluster signaling but not intracellular autocrine responses. Sci. Signal., 11, 2018, eear7388.
62. Le, R.Q., Li, L., Yuan, W., Shord, S.S., Nie, L., Habtemariam, B.A., Przepiorka, D., Farrell, A.T., Pazdur, R., FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. Oncologist 23 (2018), 943–947.
63. Lee, E.B., Fleischmann, R., Hall, S., Wilkinson, B., Bradley, J.D., Gruben, D., Koncz, T., Krishnaswami, S., Wallenstein, G.V., Zang, C., et al., ORAL Start Investigators. Tofacitinib versus methotrexate in rheumatoid arthritis. N. Engl. J. Med. 370 (2014), 2377–2386.
64. Lee, E.E., Hong, S., Martin, A.S., Eyler, L.T., Jeste, D.V., Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables. Am. J. Geriatr. Psychiatry 25 (2017), 50–61.
65. Li, J., Hu, X.F., Xing, P.X., CNTO-328 (Centocor). Curr. Opin. Investig. Drugs 6 (2005), 639–645.
66. Luiken, J.J., Arumugam, Y., Dyck, D.J., Bell, R.C., Pelsers, M.M., Turcotte, L.P., Tandon, N.N., Glatz, J.F., Bonen, A., Increased rates of fatty acid uptake and plasmalemmal fatty acid transporters in obese Zucker rats. J. Biol. Chem. 276 (2001), 40567–40573.
67. Lust, J.A., Donovan, K.A., Kline, M.P., Greipp, P.R., Kyle, R.A., Maihle, N.J., Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 4 (1992), 96–100.
68. Lyngsø, D., Simonsen, L., Bülow, J., Metabolic effects of interleukin-6 in human splanchnic and adipose tissue. J. Physiol. 543 (2002), 379–386.
69. Ma, Y., Gao, M., Sun, H., Liu, D., Interleukin-6 gene transfer reverses body weight gain and fatty liver in obese mice. Biochim. Biophys. Acta 1852 (2015), 1001–1011.
70. Masuda, K., Ripley, B., Nishimura, R., Mino, T., Takeuchi, O., Shioi, G., Kiyonari, H., Kishimoto, T., Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo. Proc. Natl. Acad. Sci. USA 110 (2013), 9409–9414.
71. Masuda, K., Ripley, B., Nyati, K.K., Dubey, P.K., Zaman, M.M., Hanieh, H., Higa, M., Yamashita, K., Standley, D.M., Mashima, T., et al. Arid5a regulates naive CD4+ T cell fate through selective stabilization of Stat3 mRNA. J. Exp. Med. 213 (2016), 605–619.
72. Matsushita, K., Takeuchi, O., Standley, D.M., Kumagai, Y., Kawagoe, T., Miyake, T., Satoh, T., Kato, H., Tsujimura, T., Nakamura, H., Akira, S., Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature 458 (2009), 1185–1190.
73. Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371 (2014), 1507–1517.
74. Mease, P., Coates, L.C., Helliwell, P.S., Stanislavchuk, M., Rychlewska-Hanczewska, A., Dudek, A., Abi-Saab, W., Tasset, C., Meuleners, L., Harrison, P., et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. Lancet 392 (2018), 2367–2377.
75. Moots, R.J., Sebba, A., Rigby, W., Ostor, A., Porter-Brown, B., Donaldson, F., Dimonaco, S., Rubbert-Roth, A., van Vollenhoven, R., Genovese, M.C., Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. Rheumatology (Oxford) 56 (2017), 541–549.
76. Murakami, M., Narazaki, M., Hibi, M., Yawata, H., Yasukawa, K., Hamaguchi, M., Taga, T., Kishimoto, T., Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family. Proc. Natl. Acad. Sci. USA 88 (1991), 11349–11353.
77. Naka, T., Narazaki, M., Hirata, M., Matsumoto, T., Minamoto, S., Aono, A., Nishimoto, N., Kajita, T., Taga, T., Yoshizaki, K., et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 387 (1997), 924–929.
78. Nakagawa, H., Tamura, T., Mitsuda, Y., Goto, Y., Kamiya, Y., Kondo, T., Wakai, K., Hamajima, N., Inverse correlation between serum interleukin-6 and iron levels among Japanese adults: a cross-sectional study. BMC Hematol., 14, 2014, 6.
79. Nakahara, H., Song, J., Sugimoto, M., Hagihara, K., Kishimoto, T., Yoshizaki, K., Nishimoto, N., Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 48 (2003), 1521–1529.
80. Nakaoka, Y., Isobe, M., Takei, S., Tanaka, Y., Ishii, T., Yokota, S., Nomura, A., Yoshida, S., Nishimoto, N., Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann. Rheum. Dis. 77 (2018), 348–354.
81. Narazaki, M., Yasukawa, K., Saito, T., Ohsugi, Y., Fukui, H., Koishihara, Y., Yancopoulos, G.D., Taga, T., Kishimoto, T., Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 82 (1993), 1120–1126.
82. Narazaki, M., Tanaka, T., Kishimoto, T., The role and therapeutic targeting of IL-6 in rheumatoid arthritis. Expert Rev. Clin. Immunol. 13 (2017), 535–551.
83. Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B.K., Ganz, T., IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 113 (2004), 1271–1276.
84. Nishimoto, N., Yoshizaki, K., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Hashimoto, J., Azuma, J., Kishimoto, T., Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 50 (2004), 1761–1769.
85. Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S., Nakano, N., Ikeda, Y., Sasaki, T., Nishioka, K., et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106 (2005), 2627–2632.
86. Nishimoto, N., Hashimoto, J., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Murata, N., van der Heijde, D., Kishimoto, T., Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann. Rheum. Dis. 66 (2007), 1162–1167.
87. Nishimoto, N., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Azuma, J., Kishimoto, T., Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod. Rheumatol. 19 (2009), 12–19.
88. Nishimoto, N., Ito, K., Takagi, N., Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod. Rheumatol. 20 (2010), 222–232.
89. Niu, G., Bowman, T., Huang, M., Shivers, S., Reintgen, D., Daud, A., Chang, A., Kraker, A., Jove, R., Yu, H., Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21 (2002), 7001–7010.
90. Norelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24 (2018), 739–748.
91. Nyati, K.K., Masuda, K., Zaman, M.M., Dubey, P.K., Millrine, D., Chalise, J.P., Higa, M., Li, S., Standley, D.M., Saito, K., et al. TLR4-induced NF-κB and MAPK signaling regulate the IL-6 mRNA stabilizing protein Arid5a. Nucleic Acids Res. 45 (2017), 2687–2703.
92. O'Shea, J.J., Gadina, M., Selective Janus kinase inhibitors come of age. Nat. Rev. Rheumatol. 15 (2019), 74–75.
93. O'Shea, J.J., Laurence, A., McInnes, I.B., Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat. Rev. Rheumatol. 9 (2013), 173–182.
94. Ogata, A., Hirano, T., Hishitani, Y., Tanaka, T., Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis. Clin. Med. Insights Arthritis Musculoskelet. Disord. 5 (2012), 27–42.
95. Ogata, A., Tanimura, K., Sugimoto, T., Inoue, H., Urata, Y., Matsubara, T., Kondo, M., Ueki, Y., Iwahashi, M., Tohma, S., et al., Musashi Study Investigators. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res. (Hoboken) 66 (2014), 344–354.
96. Okusaka, T., Ueno, H., Ikeda, M., Mitsunaga, S., Ozaka, M., Ishii, H., Yokosuka, O., Ooka, Y., Yoshimoto, R., Yanagihara, Y., Okita, K., Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma. Hepatol. Res. 45 (2015), 1283–1291.
97. Pardeo, M., Bracaglia, C., De Benedetti, F., Systemic juvenile idiopathic arthritis: New insights into pathogenesis and cytokine directed therapies. Best Pract. Res. Clin. Rheumatol. 31 (2017), 505–516.
98. Pawar, A., Desai, R.J., Solomon, D.H., Santiago Ortiz, A.J., Gale, S., Bao, M., Sarsour, K., Schneeweiss, S., Kim, S.C., Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Ann. Rheum. Dis. 78 (2019), 456–464.
99. Peters, M., Blinn, G., Jostock, T., Schirmacher, P., Meyer zum Büschenfelde, K.H., Galle, P.R., Rose-John, S., Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration. Gastroenterology 119 (2000), 1663–1671.
100. Potvin, S., Stip, E., Sepehry, A.A., Gendron, A., Bah, R., Kouassi, E., Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 63 (2008), 801–808.
101. Prakken, B., Albani, S., Martini, A., Juvenile idiopathic arthritis. Lancet 377 (2011), 2138–2149.
102. Reilley, M.J., McCoon, P., Cook, C., Lyne, P., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., et al. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. J. Immunother. Cancer, 6, 2018, 119.
103. Reinhardt, A., Yevsa, T., Worbs, T., Lienenklaus, S., Sandrock, I., Oberdörfer, L., Korn, T., Weiss, S., Förster, R., Prinz, I., Interleukin-23-Dependent γ/δ T Cells Produce Interleukin-17 and Accumulate in the Enthesis, Aortic Valve, and Ciliary Body in Mice. Arthritis Rheumatol. 68 (2016), 2476–2486.
104. Riethmueller, S., Somasundaram, P., Ehlers, J.C., Hung, C.W., Flynn, C.M., Lokau, J., Agthe, M., Düsterhöft, S., Zhu, Y., Grötzinger, J., et al. Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation. PLoS Biol., 15, 2017, e2000080.
105. Robak, T., Wierzbowska, A., Błasińska-Morawiec, M., Korycka, A., Błoński, J.Z., Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission. Mediators Inflamm. 8 (1999), 277–286.
106. Rossi, J.F., Négrier, S., James, N.D., Kocak, I., Hawkins, R., Davis, H., Prabhakar, U., Qin, X., Mulders, P., Berns, B., A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br. J. Cancer 103 (2010), 1154–1162.
107. Rutherford, A.I., Subesinghe, S., Hyrich, K.L., Galloway, J.B., Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann. Rheum. Dis. 77 (2018), 905–910.
108. Schett, G., Elewaut, D., McInnes, I.B., Dayer, J.M., Neurath, M.F., How cytokine networks fuel inflammation: Toward a cytokine-based disease taxonomy. Nat. Med. 19 (2013), 822–824.
109. Sieper, J., Porter-Brown, B., Thompson, L., Harari, O., Dougados, M., Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann. Rheum. Dis. 73 (2014), 95–100.
110. Sieper, J., Braun, J., Kay, J., Badalamenti, S., Radin, A.R., Jiao, L., Fiore, S., Momtahen, T., Yancopoulos, G.D., Stahl, N., Inman, R.D., Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann. Rheum. Dis. 74 (2015), 1051–1057.
111. Smith, S.E., Li, J., Garbett, K., Mirnics, K., Patterson, P.H., Maternal immune activation alters fetal brain development through interleukin-6. J. Neurosci. 27 (2007), 10695–10702.
112. Smolen, J.S., Weinblatt, M.E., Sheng, S., Zhuang, Y., Hsu, B., Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann. Rheum. Dis. 73 (2014), 1616–1625.
113. Smolen, J.S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann. Rheum. Dis. 76 (2017), 960–977.
114. Stenlöf, K., Wernstedt, I., Fjällman, T., Wallenius, V., Wallenius, K., Jansson, J.O., Interleukin-6 levels in the central nervous system are negatively correlated with fat mass in overweight/obese subjects. J. Clin. Endocrinol. Metab. 88 (2003), 4379–4383.
115. Stone, J.H., Tuckwell, K., Dimonaco, S., Klearman, M., Aringer, M., Blockmans, D., Brouwer, E., Cid, M.C., Dasgupta, B., Rech, J., et al. Trial of Tocilizumab in Giant-Cell Arteritis. N. Engl. J. Med. 377 (2017), 317–328.
116. Strangfeld, A., Richter, A., Siegmund, B., Herzer, P., Rockwitz, K., Demary, W., Aringer, M., Meißner, Y., Zink, A., Listing, J., Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann. Rheum. Dis. 76 (2017), 504–510.
117. Suematsu, S., Matsuda, T., Aozasa, K., Akira, S., Nakano, N., Ohno, S., Miyazaki, J., Yamamura, K., Hirano, T., Kishimoto, T., IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc. Natl. Acad. Sci. USA 86 (1989), 7547–7551.
118. Suwa, T., Hogg, J.C., English, D., Van Eeden, S.F., Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow. Am. J. Physiol. Heart Circ. Physiol. 279 (2000), H2954–H2960.
119. Takeuchi, T., Tanaka, Y., Yamanaka, H., Amano, K., Nagamine, R., Park, W., Shiozawa, K., Tsukano, M., Wei, J.C., Shao, J., et al. Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial. Mod. Rheumatol. 26 (2016), 15–23.
120. Takeuchi, T., Thorne, C., Karpouzas, G., Sheng, S., Xu, W., Rao, R., Fei, K., Hsu, B., Tak, P.P., Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study. Ann. Rheum. Dis. 76 (2017), 2001–2008.
121. Takeuchi, T., Yamanaka, H., Harigai, M., Tamamura, R., Kato, Y., Ukyo, Y., Nakano, T., Hsu, B., Tanaka, Y., Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients. Arthritis Res. Ther., 20, 2018, 42.
122. Tanaka, T., Narazaki, M., Kishimoto, T., IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol., 6, 2014, a016295.
123. Taniguchi, K., Wu, L.W., Grivennikov, S.I., de Jong, P.R., Lian, I., Yu, F.X., Wang, K., Ho, S.B., Boland, B.S., Chang, J.T., et al. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature 519 (2015), 57–62.
124. Taylor, P.C., Keystone, E.C., van der Heijde, D., Weinblatt, M.E., Del Carmen Morales, L., Reyes Gonzaga, J., Yakushin, S., Ishii, T., Emoto, K., Beattie, S., et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N. Engl. J. Med. 376 (2017), 652–662.
125. Taylor, P.C., Schiff, M.H., Wang, Q., Jiang, Y., Zhuang, Y., Kurrasch, R., Daga, S., Rao, R., Tak, P.P., Hsu, B., Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study. Ann. Rheum. Dis. 77 (2018), 658–666.
126. Teachey, D.T., Rheingold, S.R., Maude, S.L., Zugmaier, G., Barrett, D.M., Seif, A.E., Nichols, K.E., Suppa, E.K., Kalos, M., Berg, R.A., et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121 (2013), 5154–5157.
127. Timper, K., Dalmas, E., Dror, E., Rütti, S., Thienel, C., Sauter, N.S., Bouzakri, K., Bédat, B., Pattou, F., Kerr-Conte, J., et al. Glucose-Dependent Insulinotropic Peptide Stimulates Glucagon-Like Peptide 1 Production by Pancreatic Islets via Interleukin 6, Produced by α Cells. Gastroenterology 151 (2016), 165–179.
128. Timper, K., Denson, J.L., Steculorum, S.M., Heilinger, C., Engström-Ruud, L., Wunderlich, C.M., Rose-John, S., Wunderlich, F.T., Brüning, J.C., IL-6 Improves Energy and Glucose Homeostasis in Obesity via Enhanced Central IL-6 trans-Signaling. Cell Rep. 19 (2017), 267–280.
129. Torres, J., Mehandru, S., Colombel, J.F., Peyrin-Biroulet, L., Crohn's disease. Lancet 389 (2017), 1741–1755.
130. Tschaharganeh, D.F., Chen, X., Latzko, P., Malz, M., Gaida, M.M., Felix, K., Ladu, S., Singer, S., Pinna, F., Gretz, N., et al. Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology 144 (2013), 1530–1542.e12.
131. Turner, M., Díaz-Muñoz, M.D., RNA-binding proteins control gene expression and cell fate in the immune system. Nat. Immunol. 19 (2018), 120–129.
132. Uehata, T., Iwasaki, H., Vandenbon, A., Matsushita, K., Hernandez-Cuellar, E., Kuniyoshi, K., Satoh, T., Mino, T., Suzuki, Y., Standley, D.M., et al. Malt1-induced cleavage of regnase-1 in CD4(+) helper T cells regulates immune activation. Cell 153 (2013), 1036–1049.
133. van der Heijde, D., Ramiro, S., Landewé, R., Baraliakos, X., Van den Bosch, F., Sepriano, A., Regel, A., Ciurea, A., Dagfinrud, H., Dougados, M., et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann. Rheum. Dis. 76 (2017), 978–991.
134. van der Heijde, D., Baraliakos, X., Gensler, L.S., Maksymowych, W.P., Tseluyko, V., Nadashkevich, O., Abi-Saab, W., Tasset, C., Meuleners, L., Besuyen, R., et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet 392 (2018), 2378–2387.
135. van Rhee, F., Wong, R.S., Munshi, N., Rossi, J.F., Ke, X.Y., Fosså, A., Simpson, D., Capra, M., Liu, T., Hsieh, R.K., et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 15 (2014), 966–974.
136. Wallenius, K., Wallenius, V., Sunter, D., Dickson, S.L., Jansson, J.O., Intracerebroventricular interleukin-6 treatment decreases body fat in rats. Biochem. Biophys. Res. Commun. 293 (2002), 560–565.
137. Wallenius, V., Wallenius, K., Ahrén, B., Rudling, M., Carlsten, H., Dickson, S.L., Ohlsson, C., Jansson, J.O., Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med. 8 (2002), 75–79.
138. Weinblatt, M.E., Mease, P., Mysler, E., Takeuchi, T., Drescher, E., Berman, A., Xing, J., Zilberstein, M., Banerjee, S., Emery, P., The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. Arthritis Rheumatol. 67 (2015), 2591–2600.
139. Wolsk, E., Mygind, H., Grøndahl, T.S., Pedersen, B.K., van Hall, G., IL-6 selectively stimulates fat metabolism in human skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 299 (2010), E832–E840.
140. Wong, A.L., Soo, R.A., Tan, D.S., Lee, S.C., Lim, J.S., Marban, P.C., Kong, L.R., Lee, Y.J., Wang, L.Z., Thuya, W.L., et al. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann. Oncol. 26 (2015), 998–1005.
141. Wunderlich, F.T., Ströhle, P., Könner, A.C., Gruber, S., Tovar, S., Brönneke, H.S., Juntti-Berggren, L., Li, L.S., van Rooijen, N., Libert, C., et al. Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab. 12 (2010), 237–249.
142. Xie, T.X., Huang, F.J., Aldape, K.D., Kang, S.H., Liu, M., Gershenwald, J.E., Xie, K., Sawaya, R., Huang, S., Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res. 66 (2006), 3188–3196.
143. Xie, F., Yun, H., Bernatsky, S., Curtis, J.R., Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments. Arthritis Rheumatol. 68 (2016), 2612–2617.
144. Xu, E., Pereira, M.M.A., Karakasilioti, I., Theurich, S., Al-Maarri, M., Rappl, G., Waisman, A., Wunderlich, F.T., Brüning, J.C., Temporal and tissue-specific requirements for T-lymphocyte IL-6 signalling in obesity-associated inflammation and insulin resistance. Nat. Commun., 8, 2017, 14803.
145. Yamamoto, K., Goto, H., Hirao, K., Nakajima, A., Origasa, H., Tanaka, K., Tomobe, M., Totsuka, K., Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan. J. Rheumatol. 42 (2015), 1368–1375.
146. Yokota, S., Imagawa, T., Mori, M., Miyamae, T., Aihara, Y., Takei, S., Iwata, N., Umebayashi, H., Murata, T., Miyoshi, M., et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371 (2008), 998–1006.
147. Yoshizaki, K., Matsuda, T., Nishimoto, N., Kuritani, T., Taeho, L., Aozasa, K., Nakahata, T., Kawai, H., Tagoh, H., Komori, T., et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74 (1989), 1360–1367.
148. Yun, H., Xie, F., Delzell, E., Levitan, E.B., Chen, L., Lewis, J.D., Saag, K.G., Beukelman, T., Winthrop, K.L., Baddley, J.W., Curtis, J.R., Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare. Arthritis Rheumatol. 68 (2016), 56–66.
149. Zaman, M.M., Masuda, K., Nyati, K.K., Dubey, P.K., Ripley, B., Wang, K., Chalise, J.P., Higa, M., Hanieh, H., Kishimoto, T., Arid5a exacerbates IFN-γ-mediated septic shock by stabilizing T-bet mRNA. Proc. Natl. Acad. Sci. USA 113 (2016), 11543–11548.